Angiotensinogen M235T and T174M gene polymorphisms in combination doubles the risk of mortality in heart failure

Hypertension

Volumn 49, Issue 2, 2007, Pages 322-327

  Pilbrow, Anna P ^a   Palmer, Barry R ^a   Frampton, Chris M ^a   Yandle, Tim G ^a   Troughton, Richard W ^a   Campbell, Elizabeth ^a   Skelton, Lorraine ^a   Lainchbury, John G ^a   Richards, A Mark ^a   Cameron, Vicky A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Angiotensinogen; Association; Congestive; Heart failure; Mortality; Polymorphism; Single nucleotide

Indexed keywords

ANGIOTENSINOGEN; HORMONE;

AGED; ALLELE; ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENETIC ASSOCIATION; GENETIC IMMUNIZATION; GENETIC RISK; GENOTYPE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOTE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL TIME;

AGED; ALLELES; ANGIOTENSINOGEN; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEART FAILURE, CONGESTIVE; HOMOZYGOTE; HUMANS; MALE; MEDICAL RECORDS; METHIONINE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROGNOSIS; RISK ASSESSMENT; STROKE VOLUME; SURVIVAL ANALYSIS; THREONINE;

EID: 33846412237     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000253061.30170.68     Document Type: Article

References (27)

1. Lavoie JL, Sigmund CD. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology. 2003;144:2179-2183.
2. Nicholls MG, Richards AM, Agarwal M. The importance of the reninangiotensin system in cardiovascular disease. J Hum Hypertens. 1998;12:295-299.
3. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215-262.
4. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
5. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark AJ. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med. 1994;330:1629-1633.
6. Brand E, Chatelain N, Paillard F, Tiret L, Visvikis S, Lathrop M, Soubrier F, Demenais F. Detection of putative functional angiotensinogen (AGT) gene variants controlling plasma AGT levels by combined segregation-linkage analysis. Eur J Hum Genet. 2002;10:715-723.
7. Sethi AA, Nordestgaard BG, Agerholm-Larsen B, Frandsen E, Jensen G, Tybjaerg-Hansen A. Angiotensinogen polymorphisms and elevated blood pressure in the general population: the Copenhagen City Heart Study. Hypertension. 2001;37:875-881.
8. Ortlepp JR, Metrikat J, Mevissen V, Schmitz F, Albrecht M, Maya-Pelzer P, Hanrath P, Zerres K, Hoffmann R. Relation between the angiotensinogen (AGT) M235T gene polymorphism and blood pressure in a large, homogeneous study population. J Hum Hypertens. 2003;17:555-559.
9. Robinson M, Williams SM. Role of two angiotensinogen polymorphisms in blood pressure variation. J Hum Hypertens. 2004;18:865-869.
10. Wang JH, Lin CM, Wang LS, Lai NS, Chen DY, Cherng JM. Association between molecular variants of the angiotensinogen gene and hypertension in Amis tribes of eastern Taiwan. J Formos Med Assoc. 2002;101:183-188.
11. Bettinaglio P, Galbusera A, Caprioli J, Orisio S, Perna A, Arnoldi F, Bucchioni S, Noris M. Single strand conformation polymorphism (SSCP) as a quick and reliable method to genotype M235T polymorphism of angiotensinogen gene. Clin Biochem. 2002;35:363-368.
12. Hata A, Namikawa C, Sasaki M, Sato K, Nakamura T, Tamura K, Lalouel JM. Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest. 1994;93:1285-1287.
13. Jeunemaitre X, Inoue I, Williams C, Charru A, Tichet J, Powers M, Sharma AM, Gimenez-Roqueplo AP, Hata A, Corvol P, Lalouel JM. Haplotypes of angiotensinogen in essential hypertension. Am J Hum Genet. 1997;60:1448-1460.
14. Tsai CT, Fallin D, Chiang FT, Hwang JJ, Lai LP, Hsu KL, Tseng CD, Liau CS, Tseng YZ. Angiotensinogen gene haplotype and hypertension: interaction with ACE gene I allele. Hypertension. 2003;41:9-15.
15. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomoda S, Berrebi S, Sasaki M, Corvol P, Lifton RP, Lalouel J-M. A. molecular variant of angiotensinogen associated with preeclampsia. Nat Genet. 1993;4:59-61.
16. Tang W, Devereux RB, Rao DC, Oberman A, Hopkins PN, Kitzman DW, Arnett DK. Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. Am Heart J. 2002;143:854-860.
17. Buraczynska M, Pijanowski Z, Spasiewicz D, Nowicka T, Sodolski T, Widomska-Czekajska T, Ksiazek A. Renin-angiotensin system gene polymorphisms: assessment of the risk of coronary heart disease. Kardiol Pol. 2003;58:1-9.
18. Katsuya T, Koike G, Yee TW, Sharpe N, Jackson R, Norton R, Horiuchi M, Pratt RE, Dzau VJ, MacMahon S. Association of angiotensinogen gene T235 variant with increased risk of coronary heart disease. Lancet. 1995;345:1600-1603.
19. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, Moore JH, Hsu KL, Tseng CD, Liau CS, Tseng YZ. Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation. 2004;109:1640-1646.
20. Sethi AA, Tybjaerg-Hansen A, Gronholdt ML, Steffensen R, Schnohr P, Nordestgaard BG. Angiotensinogen mutations and risk for ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. Six case-control studies from the Copenhagen City Heart Study. Ann Intern Med. 2001;134:941-954.
21. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971;285:1441-1446.
22. Remme WJ, Swedberg K. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail. 2002;4:11-22.
23. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Doughty RN, Espiner EA. Immunoreactive amino-terminal pro-brain natriuretic peptide (NTPROBNP): a new marker of cardiac impairment. Clin Endocrinol (Oxf). 1997;47:287-296.
24. Nicholls MG, Espiner EA. A sensitive, rapid radioimmunoassay for angiotensin II. N Z Med J. 1976;83:399-403.
25. Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem. 1988;174:485-488.
26. Rakowski H, Appleton C, Chan KL, Dumesnil JG, Honos G, Jue J, Koilpillai C, Lepage S, Martin RP, Mercier LA, O'Kelly B, Prieur T, Sanfilippo A, Sasson Z, Alvarez N, Pruitt R, Thompson C, Tomlinson C. Canadian consensus recommendations for the measurement and reporting of diastolic dysfunction by echocardiography: from the Investigators of Consensus on Diastolic Dysfunction by Echocardiography. J Am Soc Echocardiogr. 1996;9:736-760.
27. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol. 1996;27:1214-1218.